Cara Therapeutics Stock News

Cara (CARA) delivered earnings and revenue surprises of 94.44% and 28.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

These biotech stocks have recently been responsible for a slew of rocketship emojis.

STAMFORD, Conn., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alle

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STAMFORD, Conn., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alle

Results from KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus to be presented Results from KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatiti

STAMFORD, Conn., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to all

There's good news at long last for the beaten-down biotech stock.

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals

The biotech gets an important nod from a top regulator.

Shares of CARA stock are ticking higher on Tuesday after the Cara Therapeutics' injection treatment was approved by the FDA. The post CARA Stock: The Huge FDA News Sending Cara Therapeutics Skyrocketi

Care Therapeutics Inc (NASDAQ:CARA) is seeing a influx of options activity today, following news that the U.S. Food and Drug Administration (FDA) approved its Korsuva difelikefalin injection to treat

CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.

Cara Therapeutics Inc (NASDAQ: CARA) is trading higher Tuesday after the company, and Vifor Pharma, announced the U.S. Food and Drug Administration approved KORSUVA for injection for the treatment

The FDA has approved Cara Therapeutics Inc (NASDAQ: CARA) and Vifor Pharma AG's Korsuva (difelikefalin) injection for severe-to-moderate pruritis (itching) in patients with chronic kidney disease